Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | CIT | O14578 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 2/20 | 0.30 |
| ▸ | GABRD | O14764 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.30 |
| ▸ | GABRE | P78334 | 2/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.30 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.30 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17524611 | 0.82 | ADRB2 (0.46) | ADRB2PDE2AROCK2ROCK1GABRP | |
| SCHEMBL13991742 | 0.80 | TYR (0.46) | — | |
| SCHEMBL1314596 | 0.79 | ADRB2 (0.72) | ADRB2PDE2AROCK2ROCK1CIT | |
| SCHEMBL18784066 | 0.76 | ADRB2 (0.45) | ADRB2PDE2AROCK2ROCK1CIT | |
| SCHEMBL18784067 | 0.76 | ADRB2 (0.45) | ADRB2PDE2AROCK2ROCK1CIT | |
| SCHEMBL18784068 | 0.76 | ADRB2 (0.45) | ADRB2PDE2AROCK2ROCK1CIT | |
| SCHEMBL14487023 | 0.73 | TSHR (0.47) | — | |
| SCHEMBL14085594 | 0.72 | — | — | |
| SCHEMBL2643071 | 0.72 | ADRB2 (0.56) | ADRB2PDE2AROCK2ROCK1CIT | |
| SCHEMBL19125152 | 0.71 | ADRA2A (0.46) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014033672-A1 | USE OF A RECEPTOR KINASE HAVING LYSM MOTIFS IN ORDER TO IMPROVE THE RESPONSE OF PLANTS TO LIPOCHITOOLIGOSACCHARIDES | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2014-03-06 | — | — | WO | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | ADRA2C, ADRB2, ADRB3 | ADRB2 2/4885PDE2A 201/4885ROCK2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.